ZINZANI, PIER LUIGI

ZINZANI, PIER LUIGI

Rete di Collaborazioni Statistiche Email Alert RSS Feed

Pubblicazioni

Risultati 1 - 20 di 410 (tempo di esecuzione: 0.186 secondi).

TitoloAutore(i)AnnoPeriodicoEditoreTipo
118 F-FDG PET in malignant lymphoma: significance of positive findingsCastellucci P.; Zinzani P.L.; Nanni C.; Farsad M.; Moretti A.; Alinari L.; Battista G.; Tani M.; ...Stefoni V.; Canini R.; Monetti N.; Rubello D.; Alavi A.; Franchi R.; Fanti S.2005EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING1.01 Articolo in rivista
218[F]FDG small animal PET study of sorafenib efficacy in lymphoma preclinical models.Ambrosini V; Quarta C; Zinzani PL; Nanni C; Fini M; Torricelli P; Giavaresi G; D'Errico-Grigioni ...A; Malvi D; Franchi R; Fanti S.2010THE QUARTERLY JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING1.01 Articolo in rivista
318F-FDG PET early after radiotherapy in lymphoma patients.CASTELLUCCI P; ZINZANI P; NANNI C; FARSAD M; MORETTI A; ALINARI L; BATTISTA G; PETTINATO C; MAREN...GO M; BOSCHI S; CANINI R; BACCARANI M.; MONETTI N; FANTI S.2004CANCER BIOTHERAPY & RADIOPHARMACEUTICALS1.01 Articolo in rivista
418F-FDG PET in mucosa-associated lymphoid tissue (MALT) lymphoma.Alinari L; Castellucci P; Elstrom R; Ambrosini V; Stefoni V; Nanni C;
Berkowitz A; Tani M; Farsa...d M; Franchi R; Fanti S; Zinzani PL.		2006LEUKEMIA & LYMPHOMA1.01 Articolo in rivista
518f-FDG small animal PET for early detection of human anaplastic large cell lynphoma xenografts in immunocompromised miceAmbrosini V.; Quarto C.; Zinzani P.L.; Fini M.; Giavaresi G.; Torricelli P.; Malvi D.; Nanni C.; ...Grassetto G.; Rubellos D.; Fanti S.2008ANTICANCER RESEARCH1.01 Articolo in rivista
6[18F]fluorodeoxyglucose positron emission tomography predicts survival after chemoimmunotherapy for primary mediastinal large B-cell lymphoma: results of the International Extranodal Lymphoma Study Group IELSG-26 Study.M. Martelli;L. Ceriani;E. Zucca;P. L. Zinzani;A. J. M;U. Vitolo;C. Stelitano;E. Brusamolino;M. G.... Cabras;L. Rigacci;M. Balzarotti;F. Salvi;S. Montoto;A. Lopez-Guillermo;E. Finolezzi;S. A. Pileri;A. Davies;F. Cavalli;L. Giovanella;P. W. M2014JOURNAL OF CLINICAL ONCOLOGY1.01 Articolo in rivista
790-yttrium-ibritumomab tiuxetan consolidation of fludarabine, mitoxantrone, rituximab in intermediate/high-risk follicular lymphoma: updated long-term results after a median follow-up of 7 yearsCasadei, Beatrice; Pellegrini, Cinzia; Pulsoni, Alessandro; Annechini, Giorgia; De Renzo, Amalia;... Stefoni, Vittorio; Broccoli, Alessandro; Gandolfi, Letizia; Quirini, Federica; Tonialini, Lorenzo; Morigi, Alice; Argnani, Lisa; Zinzani, Pier Luigi2016CANCER MEDICINE1.01 Articolo in rivista
8A multicenter phase II trial (SAKK 36/06) of single-agent Everolimus(RAD001) in patients with relapsed or refractory mantle cell lymphoma.Renner C; Zinzani P.L.; Gressin R; Klingbiel D; Dietrich PY; Hitz F; Bargetzi M; Mingrone W; Mart...inelli G; Trojan A; Bouabdallah K; Lohri A; Gyan E; Biaggi C; Cogliatti S; Bertoni F; Ghielmini M; Brauchli P; Ketterer N.2012HAEMATOLOGICA1.01 Articolo in rivista
9A phase 2 trial of fludarabine and mitoxantrone chemoterapy followed by yttrium-90 ibritumomab tiuxetan for patients with previously untreated, indolent, nonfollicular, non-Hodgkin lymphomaZinzani P.L.; Tani M.; Fanti S.; Stefoni V.; Musuraca G.; Vitolo U.; Perrotti A.; Fina M.; Derenz...ini E.; Baccarani M.2008CANCER1.01 Articolo in rivista
10A phase II trial of CHOP chemotherapy followed by yttrium 90 ibritumomab tiuxetan (Zevalin) for previously untreated elderly diffuse large B-cell lymphoma patients.Zinzani PL; Tani M; Fanti S; Stefoni V; Musuraca G; Castellucci P; Marchi E; Farsad M; Fina M; Pe...llegrini C; Alinari L; Derenzini E; de Vivo A; Bacci F; Pileri S; Baccarani M.2008ANNALS OF ONCOLOGY1.01 Articolo in rivista
11A phase II trial of short course fludarabine, mitoxantrone, rituximab followed by 90Y-ibritumomab tiuxetan in untreated intermediate/high-risk follicular lymphoma.Zinzani P.L.; Tani M.; Pulsoni A.; De Renzo A.; Stefoni V.; Broccoli A.; Montini G.C.; Fina M.; P...ellegrini C.; Gandolfi L.; Cavalieri E.; Torelli F.; Scopinaro F.; Argnani L.; Quirini F.; Derenzini E.; Rossi M.; Pileri S.; Fanti S.; Baccarani M.2012ANNALS OF ONCOLOGY1.01 Articolo in rivista
12ABVD versus BEACOPP for Hodgkin's lymphoma when high-dose salvage is planned.Viviani S.; Zinzani P.L.; Rambaldi A.; Brusamolino E.; Levis A.; Bonfante V.; Vitolo U.; Pulsoni ...A.; Liberati A.M.; Specchia G.; Valagussa P.; Rossi A.; Zaja F.; Pogliani E.M.; Pregno P.; Gotti M.; Gallamini A.; Rota Scalabrini D.; Bonadonna G.; Gianni A.M.; Michelangelo Foundation; Gruppo Italiano di Terapie Innovative nei Linfomi; Intergruppo Italiano Linfomi2011NEW ENGLAND JOURNAL OF MEDICINE1.01 Articolo in rivista
13Acalabrutinib in relapsed or refractory mantle cell lymphoma (ACE-LY-004): a single-arm, multicentre, phase 2 trialWang, Michael; Rule, Simon; Zinzani, Pier Luigi; Goy, Andre; Casasnovas, Olivier; Smith, Stephen ...D; Damaj, Gandhi; Doorduijn, Jeanette; Lamy, Thierry; Morschhauser, Franck; Panizo, Carlos; Shah, Bijal; Davies, Andrew; Eek, Richard; Dupuis, Jehan; Jacobsen, Eric; Kater, Arnon P; Le Gouill, Steven; Oberic, Lucie; Robak, Taduesz; Covey, Todd; Dua, Richa; Hamdy, Ahmed; Huang, Xin; Izumi, Raquel; Patel, Priti; Rothbaum, Wayne; Slatter, J. Greg; Jurczak, Wojciech2018THE LANCET1.01 Articolo in rivista
14Acalabrutinib monotherapy in patients with Waldenström macroglobulinemia: a single-arm, multicentre, phase 2 studyOwen, Roger G; McCarthy, Helen; Rule, Simon; D'Sa, Shirley; Thomas, Sheeba K; Tournilhac, Olivier...; Forconi, Francesco; Kersten, Marie José; Zinzani, Pier Luigi; Iyengar, Sunil; Kothari, Jaimal; Minnema, Monique C; Kastritis, Efstathios; Aurran-Schleinitz, Thérèse; Cheson, Bruce D; Walter, Harriet; Greenwald, Daniel; Chen, Dih-Yih; Frigault, Melanie M; Hamdy, Ahmed; Izumi, Raquel; Patel, Priti; Wei, Helen; Lee, Sun Ku; Mittag, Diana; Furman, Richard R2019THE LANCET. HAEMATOLOGY1.01 Articolo in rivista
15Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial.Hallek M, Fischer K, Fingerle-Rowson G, Fink AM, Busch R, Mayer J, Hensel M, Hopfinger G, Hess G,... von Grünhagen U, Bergmann M, Catalano J, Zinzani PL, Caligaris-Cappio F, Seymour JF, Berrebi A, Jäger U, Cazin B, Trneny M, Westermann A, Wendtner CM, Eichhorst BF, Staib P, Bühler A, Winkler D, Zenz T, Böttcher S, Ritgen M, Mendila M, Kneba M, Döhner H, Stilgenbauer S; International Group of Investigators; German Chronic Lymphocytic Leukaemia Study Group.2010THE LANCET1.01 Articolo in rivista
16Advanced/aggressive CTCL: improving the efficacy of treatment.Zinzani PL2012GIORNALE ITALIANO DI DERMATOLOGIA E VENEREOLOGIA1.01 Articolo in rivista
17Advances in management of follicular lymphoma.P. L. Zinzani2014RINSHO KETSUEKI1.01 Articolo in rivista
18ALCL: is it now a curable disease?Zinzani, Pier Luigi2017BLOOD1.01 Articolo in rivista
19ALK-anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK(+) ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the International Peripheral T-Cell Lymphoma ProjectSavage, KJ; Harris, NL; Vose, JM; Ullrich, F; Jaffe, ES; Connors, JM; Rimsza, L; Pileri, SA; Chha...nabhai, M; Gascoyne, RD; Armitage, JO; Weisenburger, DD; Zinzani, P2008BLOOD1.01 Articolo in rivista
20Allotransplant in relapsed or refractory aggressive T-cell lymphomas: retrospective monocentric analysis of 14 patientsBroccoli A;Stanzani M;Bandini G;Bonifazi F;Stefoni V;Pellegrini C;Derenzini E;Gandolfi L;Quirini ...F;Argnani L;Tschon M;Casadei B;Baccarani M;Zinzani PL2013LEUKEMIA & LYMPHOMA1.01 Articolo in rivista

Dettaglio

ZINZANI, PIER LUIGI 

DIPARTIMENTO DI MEDICINA SPECIALISTICA, DIAGNOSTICA E SPERIMENTALE 

Docenti di ruolo di Ia fascia 

P. L. Zinzani; ZINZANI L; [Zinzani PL]; P. ZINZANI; ZINZANI P; ZINZANI P.L. 

 
 
 
Powered by IRIS-about IRIS-Utilizzo dei cookie
Logo CINECA  Copyright © 2020